LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Elenco Azioni・Cogent Biosciences Inc

Cogent Biosciences Inc

Chiusa

42.07 5.47

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

40.94

Massimo

42.19

Metriche Chiave
By Trading Economics
Entrata	-7.4M -81M
EPS	-0.5
Margine di Profitto	-1,582.642
Dipendenti	205
EBITDA	-6.8M -79M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+2.37% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	4B 6.2B
Apertura precedente	36.6
Chiusura precedente	42.07

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

4.88 / 5.87 Supporto e resistenza

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 dic 2025, 16:42 UTC

Acquisizioni, Fusioni, Takeovers

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

12 dic 2025, 23:49 UTC

Acquisizioni, Fusioni, Takeovers

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dic 2025, 22:52 UTC

Discorsi di Mercato

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dic 2025, 22:32 UTC

Utili

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

12 dic 2025, 20:45 UTC

Utili

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dic 2025, 20:41 UTC

Discorsi di Mercato

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dic 2025, 20:20 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dic 2025, 19:23 UTC

Utili

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dic 2025, 18:35 UTC

Acquisizioni, Fusioni, Takeovers

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dic 2025, 18:33 UTC

Acquisizioni, Fusioni, Takeovers

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dic 2025, 18:31 UTC

Discorsi di Mercato

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dic 2025, 17:49 UTC

Utili

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dic 2025, 17:34 UTC

Acquisizioni, Fusioni, Takeovers

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12 dic 2025, 17:33 UTC

Acquisizioni, Fusioni, Takeovers

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12 dic 2025, 17:33 UTC

Acquisizioni, Fusioni, Takeovers

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12 dic 2025, 17:32 UTC

Acquisizioni, Fusioni, Takeovers

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12 dic 2025, 17:31 UTC

Acquisizioni, Fusioni, Takeovers

Orange to Buy the Stake for EU4.25B in Cash

12 dic 2025, 17:24 UTC

Discorsi di Mercato

Argentina Predicts Record Wheat Crop -- Market Talk

12 dic 2025, 17:20 UTC

Discorsi di Mercato

Utili

Tech, Media & Telecom Roundup: Market Talk

12 dic 2025, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

12 dic 2025, 17:18 UTC

Discorsi di Mercato

Utili

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12 dic 2025, 17:09 UTC

Discorsi di Mercato

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12 dic 2025, 17:09 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

12 dic 2025, 16:47 UTC

Discorsi di Mercato

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

12 dic 2025, 16:39 UTC

Discorsi di Mercato

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

12 dic 2025, 16:27 UTC

Acquisizioni, Fusioni, Takeovers

FTC Sues to Block Henkel's $725M Deal for Liquid Nails From PE Firm -- 2nd Update

12 dic 2025, 16:15 UTC

Utili

At Costco, Lots of Pie but No Special Dividend. Why the Street Didn't Like the Earnings. -- Barrons.com

12 dic 2025, 15:35 UTC

Utili

These Stocks Are Moving the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dic 2025, 14:46 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

2.37% in crescita

Previsioni per 12 mesi

Media 43.11 USD 2.37%

Alto 53 USD

Basso 30 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.